Atara Biotherapeutics (ATRA) Reports Q3 Loss of $4.20

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. PTC
4. META
5. MSFT
6. SPY
7. GMAB
8. USO
9. GOOGL
10. AMD

Go back to Atara Biotherapeutics (ATRA) Reports Q3 Loss of $4.20

Goldman Sachs Starts Atara Biotherapeutics (ATRA) at Neutral

November 10, 2014 7:20 AM EST

Goldman Sachs initiated coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Neutral rating and a price target of $30.00.

Analyst Navdeep Singh said, "Atara is an early-stage biotech developing (1) PINTA 745 for kidney dialysis patients who suffer from muscle wasting and (2) STM 434 for advanced ovarian... More

Jefferies Starts Atara Biotherapeutics (ATRA) at Buy

November 10, 2014 7:13 AM EST

Jefferies initiates coverage on Atara Biotherapeutics (NASDAQ: ATRA) with a Buy rating and a price target of $35.00.

Analyst Ryan Martins states, "ATRA has a proven management team with extensive experience in licensing and developing products. We believe ATRA's two lead clinical products, PINTA 745 and STM 434,... More